

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 54880

**Title:** Novel deletion mutation in Burton's tyrosine kinase results in X-linked agammaglobulinemia: A case report

**Reviewer's code:** 02686084

**Position:** Editorial Board

**Academic degree:** MSc

**Professional title:** Research Scientist

**Reviewer's Country/Territory:** Mexico

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-03-03

**Reviewer chosen by:** Jia-Ping Yan

**Reviewer accepted review:** 2020-04-17 05:52

**Reviewer performed review:** 2020-04-25 21:03

**Review time:** 8 Days and 15 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## **SPECIFIC COMMENTS TO AUTHORS**

In response at your invitation, I send you my final comments of the manuscript title: "A novel deletion mutation in BTK results in X-linked agammaglobulinemia: A case report and expression study". In my opinion this title reflect the main subject of the manuscript. In the other hand, the abstract summarize and reflect the work described in the manuscript, the authors provide important information about a case of a Chinese boy with a typical clinical XLA whose phenotype carrying a de novo hemizygous deletion in BTK. They identified the mutation c.902\_c.904delAAG/p. E301del) that have correlation with a predictive analysis of its effect on the tertiary structure of BTK. Also they shown that this mutation cause a significant reduction in protein stability in vitro. The manuscript does not adequately describe the status and significance of the study. In consequence its is necessary that the authors make a broader search for the study topic. The paper is accepted with some modifications: 1. The authors, will be take in consideration included the paper information with have been published, is necessary included more information and references about of mutations in BTK in X-linked agammaglobulinemia. The inclusion of the information of these already published articles will give more support to your research and results. See for example: Korean J Pediatr 2016;59(Suppl 1):S49-52 doi.org/10.3345/kjp.2016.59.11.S49 Expert Rev Clin Immunol. 2018 Jan;14(1):83-93. doi: 10.1080/1744666X.2018.1413349. Allergol Immunopathol (Madr). 2019 Jan-Feb;47(1):24-31. doi: 0.1016/j.aller.2018.03.004. Clin Immunol. 2016 Apr;165:38-44. doi: 10.1016/j.clim.2016.02.010. Scand J Immunol. 2018 Mar;87(3). doi: 10.1111/sji.